The FDA’s Oncologic Drugs Advisory Committee (ODAC) on Thursday voted 6 to 3 that AstraZeneca has not demonstrated its oral ...

New API plant at Alexion Campus signals continued commitment to Irish operations despite transatlantic trade pressures ...

While AstraZeneca has discontinued work on four assets—including one in asthma and another in acromegaly—the pharma has also ...

AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with ...

Sir Kier Starmer announces the multi-million-pound investment in the House of Commons.

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A ...

The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.

By Pushkala Aripaka and Maggie Fick April 29 (Reuters) - AstraZeneca beat first-quarter profit expectations and maintained ...

AstraZeneca reported robust first-quarter 2026 earnings, driven by strong demand for its oncology and rare disease treatments ...

CFO Aradhana Sarin breaks down the building blocks behind the revenue target and reflects on a strong Q1.